Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03816683 · ClinicalTrials.gov registry record
A Disease Registry of Patients With Mantle Cell Lymphoma
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 227
- Enrollment target
NCT03816683: Completed study, sponsored by AstraZeneca.
NCT03816683 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 227 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03816683 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 227 participants
- Enrollment target
Study Summary
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 6 months and whose treatment is ongoing at the time of enrollment.
Primary Outcome
MCL novel agent treatment types are part of the primary study objective relating to treatment patterns and will be descriptive only and use aggregated patient data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2024-03-18 |
What the finished NCT03816683 record still lists
NCT03816683 is an observational study that tracks outcomes without assigning an intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03816683 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03816683 about?
NCT03816683 is a clinical study titled "A Disease Registry of Patients With Mantle Cell Lymphoma". The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 6 months ...
What is the current status of trial NCT03816683?
This trial is currently completed. The enrollment target is 227 participants. The study started on 2019-04-01. Estimated completion is 2024-03-18.
Who is sponsoring clinical trial NCT03816683?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI